Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 425809 + memantine
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**BI 425809 + memantine** is a combination of two small molecule pharmaceuticals. BI 425809 is a selective inhibitor of Glycine transporter-1, investigated for improving cognition in patients with schizophrenia[2][4]. Memantine is an approved NMDA receptor antagonist used for moderate to severe Alzheimer's dementia[3][5]. As a combination, these drugs are studied to assess pharmacokinetics, safety, and potential synergistic effects on cognitive function and neurological health[1]. The developer and sponsor of studies involving this combination is Boehringer Ingelheim[1][2][4].
- Brand names
- AxuraEbixaMarixinoNemdatine
- Other names
- BI 425809 + memantine
02
Targets
SLC6A9 (Glycine transporter type 1)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on BI 425809 + memantine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 425809 + memantine.